Theodore (Ted) Ghorra


.(JavaScript must be enabled to view this email address)


New York

Practice Groups and Client Sectors:

Corporate,  Transactional Law

Areas of Focus:

Limited Liability Companies,  Emerging Companies,  Life Sciences,  Corporate Governance,  Securities and Capital Markets,  Medical Devices,  Securities Compliance and Offerings,  Startups and Startup Financing,  Mergers and Acquisitions
Theodore (Ted) Ghorra


Brooklyn Law School

J.D., Lisle Merit Scholar, 1968 Merit Scholar, Dean's List, Articles Editor of Law Review

St. Johns University

B.A., Dean's List

Previous Experience

  • Nixon Peabody (Partner)
  • Proskauer

Bars & Courts

  • New York

Professional Experience

Ted has closed hundreds of corporate and capital markets and other transactions, with at least half of which encompassing public offering work as underwriter’s/placement agent’s counsel ranging from boutique investment banks through the bulge brackets. He regularly works with FINRA to facilitate the clearance of transactions under its Corporate Financing Rules. Ted has represented publicly traded and privately held companies, both as transaction counsel and outside general counsel. Many of the issuers involved in these transactions are in the life sciences, energy/alternative energy, consumer products and technology sectors, but not to the exclusion of other industry sectors. He has represented as outside general counsel to numerous companies, including in the technology, medical device, last-mile service and logistics, and in the CBD health and wellness space (including publicly listed companies.) His issuer side experience includes representing companies in public and private offerings, SEC filings (‘33 Act and ‘34 Act), and to provide general corporate and securities compliance advice and corporate governance. His clients trust him to staff and oversee a broad variety of matters including their intellectual property matters, licensing transactions, oversight of litigation and white-collar matters, realty matters, trust and estate, and other matters. His clients know that he will stay involved while always maintaining an efficient, responsive and cost-conscious approach to any matter entrusted to him. Finally, Ted has been active in pro bono matters and has represented clients in the areas of Healthcare, Catholic School Education, the Holocaust Project and the arts.


  • “Bridge Financing” for a public company client - ParcelPal Technology Inc.- in the form of a convertible debenture with an institutional fund on a fixed conversion price basis, repayable in cash or in exchange for common shares, April 2020
  • Follow-on registered direct offering  for a Nasdaq listed Australian company, Integrated Media Technology Corp, on February 25, 2020, pursuant to a Securities Purchase Agreement with an accredited investor for the issuance and sale in a registered direct offering of 158,730 ordinary shares of the Company
  • Prepared and filed a Form S-8 registration statement, and advised Australian public corporation in corporate governance issues, 2020
  • Tauriga Science Inc. - executed a $5M registered Equity line of credit arrangement and filed and received effectiveness under Form S-1 pursuant to the terms of an Investment Agreement and Registration Rights Agreement with an institutional investor, consummated March 2020
  • Represented Lupagen Inc., a medical device company, in connection with a Services and Licensing Agreement with a major pharma company, 2019
  • Represented Serendipity Brands Inc., an ice cream manufacturing and distribution business, in connection with its private placement of securities, 2019
  • Represented Wells Fargo Securities as lead underwriter in an underwritten offering of common stock by Avid Bioservices, Inc.
  • Represented Spherix Incorporated, a Nasdaq-listed company in connection with its December 2015 issuance of common stock, preferred stock and warrants in a Form S-1 offering.
  • Represented Spherix Incorporated in its November 2015 licensing transaction with RPX Corporation (also a public company), whereby our client granted a license to RPX in exchange for the redemption of certain outstanding preferred stock, a release of liens on its assets and cash to our client, among other items included in the transaction.
  • Needham & Company, LLC, as underwriter’s counsel, for Nova Measuring Instruments Ltd.’s (Israel domestic) $18.4 million CMPO offering of ordinary shares
  • Cowen and Company, LLC as the exclusive Placement Agent for The Wet Seal, Inc.’s a $27 million follow-on Reg D Private Placement of public company securities
  • Spherix Incorporated, as issuer’s counsel, for aggregate financings of approximately $22MM million via registered securities offerings of common stock and common stock warrants in mid-2014 and 2015, respectively.
  • J.P. Morgan Securities, as underwriter’s counsel, in ARIAD Pharmaceuticals, Inc.’s $323 million public offering of common stock for newly FDA approved oncology therapy
  • Janney Montgomery Scott, as underwriter’s counsel, for d’ELia’s Inc.’s $15.8 million public offering of common stock, and a concurrent private placement of $21.8 million in principal amount of 7.25% convertible notes
  • Lazard Capital Markets LLC, Oppenheimer & Co. Inc., JMP Securities LLC and Maxim Group LLC, as underwriter’s counsel, for Organovo Holdings, Inc.’s $47 million public offering of common stock with over-allotment
  • PhotoMedex, Inc., as issuer’s counsel, for its $40 million concurrent registered offerings of common stock
  • Needham & Company, LLC and D.A. Davidson & Co. as underwriter’s counsel, for Radisys Corporation’s $23 million follow-on public offering of Common Stock
  • Lazard Capital Markets LLC, Cowen and Company LLC, JMP Securities LLC, Wedbush PacGrow Life Sciences and Canaccord Genuity, as underwriter’s counsel, for Sarepta Therapeutics, Inc.’s $125 million public offering of common stock
  • Lazard Capital Markets LLC, as underwriter’s counsel, for Globalstar Inc.'s $38 million private placement of Convertible Senior Unsecured Notes and Warrants to Purchase Common Stock
  • Barclays Capital, Inc., as underwriters' counsel, Halozyme Therapeutics, Inc.'s $72 million public offering of common stock
  • Lazard Capital Markets LLC, as placement agent’s counsel, for Evergreen Energy Inc.’s at-the-market program to sell up to $10 million in common stock
  • Kinderhook Partners L.P., as investor counsel, for Patient Safety Technologies, Inc.’s $7.1 million offering of common stock
  • Lazard Capital Markets LLC, as underwriter’s counsel, for Harvest Natural Resources Inc.’s $32 million registered direct offering of senior convertible notes
  • 2015 New York Super Lawyer